Navigation Links
EnzySurge Receives FDA Approval for SilverStream(TM) Innovative Wound Management Solution
Date:12/15/2009

ROSH HA'AYIN, Israel, December 15 /PRNewswire/ -- EnzySurge Ltd. (EnzySurge), a provider of innovative solutions for the advanced chronic wound management market, announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its new SilverStream(TM) solution for prescription use. The FDA also cleared DermaSept, an Over-the-Counter version of the SilverStream product.

EnzySurge is the developer of the DermaStream(R) product line. DermaStream is a line of woundcare devices that allows for the continuous streaming of fresh therapeutic solutions, such as SilverStream, over the wound bed. The treatment provides constant removal of foreign material, exudate, micro-organisms and debris while creating negative pressure over the wound.

SilverStream may be either applied directly onto the wound or by the disposable DermaStream(R) device. According to Dr. Noa Hadar and Prof. Amihay Freeman who led the development, SilverStream is a hypertonic solution that contains very low concentration of preservative silver ions. "SilverStream has demonstrated remarkable capabilities by in-vitro testing inhibiting the growth of drug-resistant clinical bacterial strains, yeast and fungi upon contact in-vitro", stated Freeman.

SilverStream is intended for use under the supervision of a healthcare professional for management and moisturizing of wounds such as stage I-IV pressure ulcers, stasis ulcers, diabetic foot ulcers, post-surgical wounds, first and second degree burns, cuts abrasions and minor skin irritations. DermaSept is intended for the management and moisturizing of minor cuts, minor burns, abrasions and irritated areas.

"We are extremely pleased to receive FDA clearance for this unique product", says Amir Shiner Chief Executive Officer of EnzySurge. "We believe that SilverStream is a powerful wound management solution and will be a significant addition to the DermaStream(R) product line, which is intended to become the wound management system of choice. We are poised to launching SilverStream to market in 2010 with our U.S. partner, the Virginia Biosciences Commercialization Center."

The treatment of chronic wounds (such as diabetic, pressure and venous ulcers) is expensive, laborious and requires ongoing application and monitoring by a skilled caregiver. The global market for chronic wound products amounted $3.2 billion in 2008 and is expected grows to $4.1 billion by 2011.

"The recent achievements of EnzySurge and especially this FDA approval for SilverStream, represent significant opportunities for EnzySurge in the global wound care market in the near future", says Shiner.

About EnzySurge Ltd.

EnzySurge Ltd. is a developer and provider of innovative solutions for the treatment and management of chronic wounds. EnzySurge's DermaStream(R) platform offers a new and unique wound treatment modality by continuously streaming a fresh supply of advanced therapeutic solutions to a controlled wound environment. DermaStream is designed to deliver effective, affordable and easy-to-use wound treatment throughout all phases of chronic wound treatment from debridement, through regeneration to wound closure. The EnzySurge product line is intended for use in hospitals, clinics and for home care.

    For further details:

    Amir Shiner, CEO
    Mobile: +972-54-3030294
    Tel: +972-3-6227600
    http://www.dermastream.com

SOURCE EnzySurge Ltd


'/>"/>
SOURCE EnzySurge Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award
2. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
3. Greenway Medical Technologies PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification
4. Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration
5. Mylan Receives Approval for Generic Version of Antiepileptic Keppra(R) 1000 mg
6. Dynatronics Receives 180-Day NASDAQ Extension
7. ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System
8. AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens
9. Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress
10. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
11. Giant Eagle(R) Pharmacy Receives Award for Operational Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Calif. , March 27, 2017  Cryoport, Inc. ... that it intends to offer shares of common stock ... registration statement on file with the Securities and Exchange ... and other conditions, and there can be no assurance ... completed, or as to the actual size or terms ...
(Date:3/27/2017)... N.Y. , March 27, 2017 To mark ... U.S.A. , Inc., a leader in digital imaging solutions, ... Expo East convention, held at New York,s ... 2017. Save Your Vision Month, sponsored by the American Optometric ... and the importance of receiving comprehensive eye exams. In recognition ...
(Date:3/27/2017)... and VANCOUVER, British Columbia, March 27, 2017 /PRNewswire/ ... (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical ... patients with urological diseases, today reported fourth quarter ... corporate highlights. Key Corporate Highlights: ... Development for Localized Prostate Cancer. During 2016, the ...
Breaking Medicine Technology:
(Date:3/28/2017)... WASHINGTON, DC (PRWEB) , ... March 28, 2017 , ... ... and Dr. Toni Bark , WHAT: , Medical doctors and PhD scientists will speak ... have written to President Trump in support of an independent vaccine safety commission. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... The ... MHA, FRBMA, has begun to serve as its new executive director. Mr. Still was ... Executive Search Committee. , “Bob, as he is known to our members, has ...
(Date:3/28/2017)... Calif. (PRWEB) , ... March 28, 2017 , ... ... its leading physicians, Paul Yost, will begin serving as new board chair for ... this month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology ... two biometric time and attendance tracking products: the new NCheck Cloud Bio Attendance ... Bio Attendance uses biometric face recognition to enable users to check in and ...
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER TOLEDO Process Analytics ... power plant water and steam. , Chlorides and sulfates cause pitting and stress ... extensive maintenance and unplanned shutdowns. Monitoring these ions at low ppb levels has ...
Breaking Medicine News(10 mins):